MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamacardio.2016.4801

Медицинская библиотека · JAMA cardiology · 2017

Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial.

Silva Marly Conceição, Magalhães Tiago Augusto, Meira Zilda Maria Alves, Rassi Carlos Henrique Reis Esselin, Andrade Amanda Cristina de Souza, Gutierrez Paulo Sampaio, Azevedo Clerio Francisco, Gurgel-Giannetti Juliana, Vainzof Mariz, Zatz Mayana, Kalil-Filho Roberto, Rochitte Carlos Eduardo

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

IMPORTANCE

In Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), interventions reducing the progression of myocardial disease could affect survival.

OBJECTIVE

To assess the effect of early angiotensin-converting enzyme (ACE) inhibitor therapy in patients with normal left ventricular function on the progression of myocardial fibrosis (MF) identified on cardiovascular magnetic resonance (CMR).

DESIGN, SETTING, AND

PARTICIPANTS

A randomized clinical trial conducted in 2 centers included 76 male patients with DMD or BMD undergoing 2 CMR studies with a 2-year interval for ventricular function and MF assessment. In a non-intent-to-treat trial, 42 patients with MF and normal left ventricular ejection fraction (LVEF) were randomized (1:1) to receive or not receive ACE inhibitor therapy. The study was conducted from June 26, 2009, to June 30, 2012. Data analysis was performed from June 30, 2013, to October 3, 2016.

INTERVENTIONS: Randomization (1:1) to receive or not receive ACE inhibitor therapy.

MAIN OUTCOMES AND MEASURES: Primary outcome was MF progression from baseline to the 2-year CMR study.

RESULTS

Of the 76 male patients included in the study, 70 had DMD (92%) and 6 had BMD (8%); mean (SD) age at baseline was 13.1 (4.4) years. Myocardial fibrosis was present in 55 patients (72%) and LV systolic dysfunction was identified in 13 patients (24%). Myocardial fibrosis at baseline was an independent indicator of lower LVEF at follow-up (coefficient [SE], -0.16 [0.07]; P = .03). Among patients with MF and preserved LVEF (42 [55%]), those randomized (21 patients in each arm) to receive ACE inhibitors demonstrated slower MF progression compared with the untreated group (mean [SD] increase of 3.1% [7.4%] vs 10.0% [6.2%] as a percentage of LV mass; P = .001). In multivariate analysis, ACE inhibitor therapy was an independent indicator of decreased MF progression (coefficient [SE], -4.51 [2.11]; P = .04). Patients with MF noted on CMR had a higher probability of cardiovascular events (event rate, 10 of 55 [18.2%] vs 0 of 21 [0%]; log-rank P = .04).

CONCLUSIONS AND RELEVANCE: In this 2-year, follow-up, randomized clinical trial of patients with Duchenne or Becker muscular dystrophy whose LVEF was preserved and MF was present as determined on CMR, ACE inhibitor therapy was associated with significantly slower progression of MF. The presence of MF was associated with worse patient prognosis.

TRIAL REGISTRATION: clinicaltrials.org Identifier: NCT02432885.

Для цитирования: Silva Marly Conceição, Magalhães Tiago Augusto, Meira Zilda Maria Alves, Rassi Carlos Henrique Reis Esselin, Andrade Amanda Cristina de Souza, Gutierrez Paulo Sampaio, Azevedo Clerio Francisco, Gurgel-Giannetti Juliana, Vainzof Mariz, Zatz Mayana, Kalil-Filho Roberto, Rochitte Carlos Eduardo. Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial.. JAMA cardiology. 2017. DOI: 10.1001/jamacardio.2016.4801.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.